Cargando…
Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance
The predictive factors of long-term clinical benefits in patients with hepatitis C virus (HCV)—related liver cirrhosis after Direct Antiviral Agents (DAA) treatment are still undefined. The aim of this study was to identify any predictors of liver failure, hepatocellular carcinoma (HCC) and/or death...
Autores principales: | Franzè, Maria Stella, Filomia, Roberto, Caccamo, Gaia, Pitrone, Concetta, Alibrandi, Angela, Saitta, Carlo, Caspanello, Amalia Rita, Asero, Clelia, Arcadi, Vittoria, Raimondo, Giovanni, Cacciola, Irene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699534/ https://www.ncbi.nlm.nih.gov/pubmed/36579534 http://dx.doi.org/10.3390/jpm12111794 |
Ejemplares similares
-
Over time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
por: Cacciola, Irene, et al.
Publicado: (2021) -
Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography
por: Filomia, Roberto, et al.
Publicado: (2016) -
High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease
por: Asero, Clelia, et al.
Publicado: (2023) -
EXPERIMENTAL HYPERGAMMAGLOBULINEMIA IN MINK
por: Henson, James B., et al.
Publicado: (1962) -
Hypergammaglobulinemia in the pediatric population
por: Lo, Mindy S, et al.
Publicado: (2012)